A string of disappointing results for Merck KGaA’s bintrafusp alfa culminated in the termination of the German firm’s $4.2bn partnership with GlaxoSmithKline plc for the anticancer product at the end of September.
Bintrafusp alfa had been an important asset for both companies. GSK paid $360m upfront for a stake in the bifunctional...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?